ADC Therapeutics SA Reports Q2 2026 Financial Results

What Happened
ADC Therapeutics SA (ADCT) filed a Form 8-K on August 13, 2026 to announce its financial results for the three and six months ended June 30, 2026. The company issued a press release and made a corporate presentation the same day; both documents are attached to the 8-K and incorporated by reference.

Key Details

• Filing date: August 13, 2026 (Form 8-K Items 2.02 and 7.01).
• Reporting periods: three and six months ended June 30, 2026.
• Documents posted: Press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) containing the announced financial results and related disclosures.
• The 8-K does not include other corporate actions (e.g., executive changes or M&A) beyond the earnings disclosure and presentation release.

Why It Matters
The press release and presentation contain ADC Therapeutics’ updated quarterly financial results and related information investors use to assess revenue, expenses, cash position and operating trends. Retail investors should review the attached press release and presentation for the company’s reported figures, any commentary on operations or guidance, and potential impacts on valuation or near-term outlook.